Invention Grant
US09505751B2 Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
有权
取代的[1,2,4]三唑并[1,5-a]吡嗪作为磷酸二酯酶抑制剂
![Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors](/docs/US/2016-11-29/US09505751B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
- Patent Title (中): 取代的[1,2,4]三唑并[1,5-a]吡嗪作为磷酸二酯酶抑制剂
-
Application No.: US14409866Application Date: 2013-06-19
-
Publication No.: US09505751B2Publication Date: 2016-11-29
- Inventor: John Emmerson Campbell , Phillip G. Jones , Scott Malcolm
- Applicant: SUNOVION PHARMACEUTICALS INC.
- Applicant Address: US MA Marlborough
- Assignee: Sunovion Pharmaceuticals Inc.
- Current Assignee: Sunovion Pharmaceuticals Inc.
- Current Assignee Address: US MA Marlborough
- International Application: PCT/US2013/046483 WO 20130619
- International Announcement: WO2013/192273 WO 20131227
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D241/38 ; C07D487/04 ; C07D471/04 ; A61K31/437 ; A61K31/4709 ; C07D519/00
![Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors](/abs-image/US/2016/11/29/US09505751B2/abs.jpg.150x150.jpg)
Abstract:
Provided herein are substituted triazolopyrazine phosphodiesterase inhibitors, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorder.
Public/Granted literature
- US20150322090A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF Public/Granted day:2015-11-12
Information query
IPC分类:
